AMAG Pharmaceuticals, Inc. (AMAG) SVP Sells $98,760.00 in Stock
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the sale, the senior vice president now owns 28,336 shares in the company, valued at approximately $566,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Julie Krop also recently made the following trade(s):
- On Monday, May 1st, Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock. The shares were sold at an average price of $24.45, for a total value of $46,234.95.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded up 0.50% on Friday, reaching $20.05. The company had a trading volume of 698,030 shares. AMAG Pharmaceuticals, Inc. has a 52 week low of $16.00 and a 52 week high of $36.83. The firm’s market capitalization is $702.65 million. The stock’s 50 day moving average is $18.02 and its 200 day moving average is $23.21.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. The firm had revenue of $139.47 million during the quarter, compared to analysts’ expectations of $150.32 million. During the same period last year, the company earned ($0.22) earnings per share. The business’s revenue for the quarter was up 27.6% compared to the same quarter last year. On average, equities analysts anticipate that AMAG Pharmaceuticals, Inc. will post $5.40 EPS for the current year.
A number of hedge funds have recently bought and sold shares of AMAG. Clark Estates Inc. NY raised its stake in AMAG Pharmaceuticals by 16.5% in the first quarter. Clark Estates Inc. NY now owns 120,100 shares of the specialty pharmaceutical company’s stock worth $2,708,000 after buying an additional 17,000 shares during the period. Louisiana State Employees Retirement System raised its stake in AMAG Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,000 shares of the specialty pharmaceutical company’s stock worth $316,000 after buying an additional 200 shares during the period. Fox Run Management L.L.C. purchased a new stake in AMAG Pharmaceuticals during the first quarter worth $992,000. Cornerstone Financial Partners LLC raised its stake in AMAG Pharmaceuticals by 306.3% in the first quarter. Cornerstone Financial Partners LLC now owns 49,492 shares of the specialty pharmaceutical company’s stock worth $1,116,000 after buying an additional 37,312 shares during the period. Finally, Bank of Montreal Can raised its stake in AMAG Pharmaceuticals by 4,071.4% in the first quarter. Bank of Montreal Can now owns 66,492 shares of the specialty pharmaceutical company’s stock worth $1,500,000 after buying an additional 64,898 shares during the period.
Several research analysts have recently commented on AMAG shares. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Jefferies Group LLC set a $40.00 price objective on AMAG Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, March 18th. ValuEngine downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Barclays PLC reiterated a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a report on Monday, May 15th. Finally, Citigroup Inc. decreased their price objective on AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a report on Friday, July 7th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $28.09.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.